These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17473302)

  • 1. FDA responds to institute of medicine drug safety recommendations--in part.
    Psaty BM; Charo RA
    JAMA; 2007 May; 297(17):1917-20. PubMed ID: 17473302
    [No Abstract]   [Full Text] [Related]  

  • 2. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
    Psaty BM; Burke SP
    N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
    [No Abstract]   [Full Text] [Related]  

  • 3. Blueprint for a stronger Food and Drug Administration.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2006 Oct; 355(17):1821. PubMed ID: 17030844
    [No Abstract]   [Full Text] [Related]  

  • 4. The Institute of Medicine report on the FDA: where is the science?
    Philipson T; Jena AB; Sun E
    Health Econ; 2007 Mar; 16(3):219-21. PubMed ID: 17315264
    [No Abstract]   [Full Text] [Related]  

  • 5. The FDA and the IOM report.
    Galson SK
    N Engl J Med; 2007 Dec; 357(24):2520-1; author reply 2521-2. PubMed ID: 18077820
    [No Abstract]   [Full Text] [Related]  

  • 6. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 7. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.
    Bunney WE; Azarnoff DL; Brown BW; Cancro R; Gibbons RD; Gillin JC; Hullett S; Killam KF; Kupfer DJ; Krystal JH; Stolley PD; French GS; Pope AM
    Arch Gen Psychiatry; 1999 Apr; 56(4):349-52. PubMed ID: 10197830
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.
    Tilson HH; Madre LK; Califf RM
    Clin Pharmacol Ther; 2007 Aug; 82(2):118-21. PubMed ID: 17632533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA in 2006: reasons for optimism.
    Chabner BA; Roberts TG
    Oncologist; 2007 Mar; 12(3):247-9. PubMed ID: 17405888
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA unveils 25 initial 510(k) changes, refers controversial recommendations to the Institute of Medicine (IOM).
    Gilmore M; Hylak-Reinholtz JJ
    Health Care Law Mon; 2011 Jun; 2011(6):2-7. PubMed ID: 21748924
    [No Abstract]   [Full Text] [Related]  

  • 11. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 12. IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
    Kuehn BM
    JAMA; 2012 Jun; 307(23):2475-6. PubMed ID: 22797430
    [No Abstract]   [Full Text] [Related]  

  • 13. IOM: overhaul drug safety monitoring.
    Kuehn BM
    JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
    [No Abstract]   [Full Text] [Related]  

  • 14. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 15. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 16. Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Jan; 99(2):104-7. PubMed ID: 17227990
    [No Abstract]   [Full Text] [Related]  

  • 17. IOM panel mulls over adverse-event reporting.
    Young D
    Am J Health Syst Pharm; 2005 Dec; 62(24):2590-1. PubMed ID: 16333055
    [No Abstract]   [Full Text] [Related]  

  • 18. Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.
    Crawford LM
    Food Drug Law J; 2005; 60(2):99-102. PubMed ID: 16097087
    [No Abstract]   [Full Text] [Related]  

  • 19. Sweeping changes, or a sweep under the rug?
    Barie PS
    Surg Infect (Larchmt); 2006 Oct; 7(5):407-8. PubMed ID: 17083306
    [No Abstract]   [Full Text] [Related]  

  • 20. Can the Institute of Medicine review the FDA?
    Carroll BJ
    Nat Med; 2005 Apr; 11(4):369. PubMed ID: 15812509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.